CLRB News and Press, Cellectar Biosciences Inc. From 12/06/20

Are These Biotech Penny Stocks On Your Radar This Week? When it comes to finding penny stocks to buy, speculation can fuel momentum. One of the top sectors that play off of this speculation well is biotech. Right now, biotech stocks are some of the hottest in the market. This is...

Gainers: Sutro Biopharma (STRO) +33%, Merrimack Pharmaceuticals (MACK) +18%, Evogene (EVGN) +18%, BioCryst Pharmaceuticals (BCRX) +16%, PDS Biotechnology (PDSB) +15%.Losers: Precision BioSciences DTIL -21%, Cortexyme CRTX -17%, Chembio Di...

Are These On Your List Of Top Penny Stocks To Watch This Week? When you talk about penny stocks and analyst ratings, it’s sometimes hard to fathom the idea of certain stocks rallying so big. In many cases, not only do analysts slap a buy rating on these stocks. They also put ...

Gainers: Enlivex Therapeutics (ENLV) +24%, Cellectar Biosciences (CLRB) +18%, Omeros (OMER) +15%, Trxade Group (MEDS) +13%, AlloVir (ALVR) +10%.Losers: ReWalk Robotics (RWLK) -11%, Precision BioSciences (DTIL) -11%, Merrimack Pharmaceutic...

Gainers: Catabasis Pharmaceuticals (CATB) +44%, iBio (IBIO) +21%, Cellectar Biosciences (CLRB) +21%, Intec Pharma (NTEC) +18%, Sio Gene Therapies (SIOX) +18%.Losers: Ovid Therapeutics (OVID) -55%, Auris Medical (EARS) -35%, iRhythm Techno...

Why Are These Penny Stocks Gaining Attention In December 2020? As 2020 comes to a close, there are plenty of penny stocks to watch . While finding penny stocks may seem like a daunting task at first, it can be made much easier with a few simple tips. The first tip that all inve...

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the ...

Cellectar Biosciences ([[CLRB]] -0.9%) has announced interim results from Phase 1 study evaluating CLR 131 in relapsed or refractory brain tumors, specifically high grade gliomas, high risk neuroblastomas and select soft tissue sarcomas.Four dose levels (15, 30, 45 and 60mCi/m2 ) have been ev...

FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced CLR 131 has demonstrated p...

Our analysis concludes CLRB appears a worthwhile speculative investment at $1.15 per share primarily because the potential upside dramatically outweighs the risk of downside based on, among other things, the results of CLRB's Phase 2 trial (called CLOVER-1) of its CLR131 candidate therapy in p...